- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02008149
FES Rowing for Skeletal Health After SCI (FES-R)
Using Musculoskeletal Models to Assess FES Rowing for Skeletal Health After SCI
Study Overview
Detailed Description
In this study the investigators expect to enroll a total of 10 participants with SCI. Five participants will be assigned to a Standard-of-Care (control) group and five participants will be assigned to an FES-rowing intervention group. Group assignment will be partly based on the preference of each potential participant and their willingness to make the necessary time commitment required for participation in a given group, with the added goal, to the extent possible, of matching the two groups for age, gender and time since injury. Only those individuals who have a strong desire to participate in a regular exercise program and who express a willingness to travel to VA Palo Alto the necessary number of times per week to perform FES-rowing will be potential candidates for inclusion in the rowing group.
Bone density measurements for both the Standard-of-Care group and the FES-rowing group will be performed using Dual energy X-ray Absorptiometry (DXA) and peripheral Quantitative Computed Tomography (pQCT). The Standard-of-Care group will undergo no other research procedures.
The muscle conditioning program is accomplished through electrical stimulation of the quadriceps and hamstring muscles using a 4-channel electrical stimulator that applies stimulation using surface electrodes adhered using gel to the skin overlying the quadriceps and hamstrings muscles. The muscle strengthening initially takes place three times per week, sixty minutes per session, progressing up to five sessions per week, for approximately 8 weeks. The muscle strengthening program ensures that subjects have sufficient muscle strength and endurance before they embark on the rowing program. Following the 8-week muscle strengthening program, subjects will begin FES-rowing, with three sessions per week, thirty minutes per session for the following 28 weeks. In the FES-rowing group, the investigators will measure isometric knee extension strength at the start of week 0, and at the end of weeks 12, 24 and 36.
For the rowing group, the investigators will capture 3D kinetics and kinematics in the motion capture laboratory during FES-rowing at the end of weeks 12, 24 and 36. Kinematics during rowing will be collected from fifty passive retro-reflective markers that will be placed on each participant to capture the position and orientation of the 12 interconnected body segments used to represent each subject.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Palo Alto, California, United States, 94304-1290
- VA Palo Alto Health Care System, Palo Alto, CA
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Subjects in the rowing groups:
- male and female SCI outpatients or inpatients
- have a C7 to T12, ASIA-A or ASIA-B, spinal cord injury
- be at least 18 years old
- have their physician's clearance to exercise
- between 3 and 24 months post spinal cord injury*
- minimum passive hip flexion range of motion (ROM) from 20 to 100 deg
- minimum passive knee flexion ROM from 20 to 100 deg
- minimum passive ankle ROM from +10 deg (dorsi-flexion) to -15 deg (plantar-flexion)
- currently use a manual wheelchair
- be able to perform independent and safe transfers to and from their wheelchair *There is no time post injury restriction for subjects in the experience rower group
Subjects in the control group:
- male and female SCI outpatients or inpatients
- have a C5 to T12, ASIA-A or ASIA-B, spinal cord injury
- be at least 18 years old
- between 3 and 24 months post spinal cord injury
- be able to perform safe transfers to and from their wheelchair, either independently or with assistance
Exclusion Criteria:
- pregnant women
- women of childbearing potential not practicing a reliable method of contraception
- women who are post-menopausal
- have mechanical instability of the spine
- resting blood pressure higher than 140/90
- a grade 1 or greater, sacral, gluteal or ischial pressure ulcer
- history of low trauma, lower limb fracture since SCI
- renal disease
- current osteomyelitis
- current thrombosis/hemorrhage
- cancer
- other neurological disease (i.e. stroke, peripheral neuropathy, myopathy)
- any implanted electronic device
- active treatment for epilepsy
- regular use of tobacco
- known coronary artery disease
- family history of sudden cardiac death
- current use of cardioactive medications, e.g., for treatment of congestive heart failure or arrhythmia
current use of medications that can affect bone density and fracture risk including:
- bisphosphonates
- parathyroid hormone (PTH) and PTH analogs
- androgenic steroids
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Standard of care group
SCI individuals receiving conventional rehab
|
|
|
Experimental: FES-rowing group
Individuals with SCI participating in an FES-rowing program
|
Individuals with SCI will use the rowing exerciser to see if there is a benefit to skeletal health in the lower limbs.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Bone Mineral Density
Time Frame: 0, 16, 29 and 43 weeks
|
Bone mineral density at the distal femur at 0, 16, 29 and 43 weeks measured using peripheral quantitative computed tomography scanning.
|
0, 16, 29 and 43 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Gary Beaupre, PhD, VA Palo Alto Health Care System, Palo Alto, CA
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- B1410-P
- 5I21RX001410-02 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.